Catalog No.
Product Name
Application
Product Information
Citations
-
COX Inhibitor
Pifoxime is a potent inhibitor of cyclooxygenase (COX-1 and COX-2), classified as a non-steroidal anti-inflammatory drug (NSAID). It demonstrates significant anti-inflammatory properties, making it suitable for various research applications, including neuropsychiatric studies. Pifoxime's ability to modulate inflammation can provide valuable insights into the underlying mechanisms of inflammatory processes in different biological contexts. -
COX-2 Inhibitor
Esculentic acid is a selective inhibitor of cyclooxygenase-2 (COX-2), exhibiting significant anti-inflammatory properties. As a pentacyclic triterpenoid derived from the Chinese herb Phytolacca esculenta, it is valuable in research focused on inflammation and related pathways. This compound is applicable in studies targeting the modulation of COX-2 activity and its implications in various inflammatory conditions. -
COX Inhibitor
SC-75416 is a selective inhibitor of cyclooxygenase-2 (COX-2), primarily designed to mitigate pain and inflammation. Its pharmacokinetic/pharmacodynamic (PK/PD) model has been utilized to develop clinical trial simulations that support its analgesic efficacy, demonstrated to exceed that of ibuprofen in post-oral surgery pain models. The results from these simulations and subsequent clinical trials indicate that SC-75416 offers superior pain relief, underscoring its potential as a valuable therapeutic agent for managing postoperative pain. -
COX-1/2 Inhibitor
Diclofenac amide is a prodrug that functions as an oral inhibitor of cyclooxygenase-1 and -2 (COX-1/2), effectively reducing the synthesis of prostaglandins and thromboxanes. This compound demonstrates significant anti-inflammatory activity in the carrageenan-induced rat paw edema model while preserving gastric integrity, making it a valuable tool for studying inflammation and pain mechanisms. Its favorable safety profile and effectiveness position it as a promising candidate in pharmacological research. -
COX Inhibitor
Bromfenac is a potent and orally active inhibitor of cyclooxygenases (COX-1 and COX-2), exhibiting IC50 values of 5.56 nM and 7.45 nM, respectively. This selective COX inhibition makes Bromfenac valuable in the study of ocular inflammation and pain management. Its effectiveness in reducing inflammation positions it as a useful tool for researchers investigating inflammatory pathways in various biological contexts. -
COX
C2 Ceramide (d14:1/2:0) is a lipid molecule that selectively targets cyclooxygenase-2 (COX-2). This compound demonstrates a robust binding affinity for the COX-2 protein, making it a valuable tool for studying COX-2 overexpression in various disease contexts. C2 Ceramide (d14:1/2:0) can be utilized in research focused on inflammatory pathways and potential therapeutic interventions involving COX-2 modulation. -
COX Inhibitor
Naproxen ethyl ester is a nonsteroidal anti-inflammatory drug that functions primarily as a cyclooxygenase (COX) inhibitor. This compound effectively alleviates pain, fever, swelling, and stiffness by obstructing the actions of COX enzymes. The R-(-)-isomer of Naproxen ethyl ester is noted for its enhanced immunogenicity, demonstrating a Michaelis-Menten constant (K(M)) of 6.67 mM and exhibiting a catalytic efficiency that is 5.8 x 10^4 times greater than that of non-catalytic reactions. This compound is useful in pain management and inflammation research. -
COX-1 Inhibitor
COX-1-IN-5 is a highly selective COX-1 inhibitor, demonstrating an IC50 of 1 nM for COX-1 and greater than 0.1 μM for COX-2, thereby showing over 1000-fold selectivity for COX-1. This compound exhibits significant anti-inflammatory, antipyretic, analgesic, antithrombotic, and potential anti-cancer properties. COX-1-IN-5 is suitable for investigating COX-mediated diseases, including inflammatory conditions and pain. Additionally, when radiolabeled with 11C, it serves as a selective PET tracer for in vivo imaging of COX-1 distribution and target engagement. -
COX Inhibitor
Flunoxaprofen is an orally active cyclooxygenase (COX) inhibitor that exhibits significant anti-inflammatory properties. In preclinical models, such as rat paw edema assays, Flunoxaprofen has demonstrated efficacy in reducing inflammation. This compound may be utilized in research focused on immune system disorders, including arthritis and related inflammatory conditions. -
COX-2 Inhibitor
COX-2-IN-19 is a potent inhibitor of cyclooxygenase-2 (COX-2), exhibiting an IC50 value of 1.76 μM. This compound demonstrates significant in vivo anti-inflammatory activity, making it a valuable tool for research in inflammation and pain pathways. COX-2-IN-19 is suitable for studies focused on the modulation of COX-2-related biological processes in various disease models. -
COX Inhibitor
COX-1/2-IN-4 is a dual inhibitor of cyclooxygenase enzymes COX-1 and COX-2, exhibiting IC50 values of 0.239 μM and 0.191 μM, respectively. This compound demonstrates moderate anticancer activity against COLO205 and B16F1 cancer cell lines, with IC50 values of 30.79 μM and 74.15 μM. It serves as a valuable tool for research into the roles of COX enzymes in inflammation and cancer. -
COX-2/15-LOX Inhibitor
COX-2/15-LOX-IN-1 is a dual inhibitor of cyclooxygenase-2 (COX-2) and 15-lipoxygenase (15-LOX), exhibiting IC50 values of 10.65 μM for COX-1, 0.075 μM for COX-2, and 2.98 μM for 15-LOX. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for research into inflammatory pathways and related diseases. Its ability to modulate key enzymes involved in arachidonic acid metabolism positions COX-2/15-LOX-IN-1 as a promising candidate for therapeutic investigation in inflammatory conditions. -
COX-2 Inhibitor
COX-2-IN-34 is a selective and orally active inhibitor of cyclooxygenase-2 (COX-2), exhibiting an IC50 of 0.42 μM. This compound demonstrates anti-inflammatory properties without the associated gastric ulcer toxicity often seen with non-selective COX inhibitors. COX-2-IN-34 is suitable for research applications focused on inflammation and related pathways. -
COX Inhibitor
ZXX2-77 is a selective inhibitor of cyclooxygenase-1 (COX-1) from the benzenesulfonylanilide compound class. It demonstrates significant COX-1 inhibitory activity in vitro, making it a candidate for pain management without the gastrointestinal side effects commonly associated with traditional analgesics. While its low oral absorption contributes to a reduced analgesic effect in vivo, its unique profile highlights the potential for developing effective COX-1 selective inhibitors that mitigate gastric damage. Further exploration of ZXX2-77 and its derivatives may lead to new therapeutic options for pain relief. -
COX-2 Inhibitor
COX-2-IN-40 is a selective COX-2 inhibitor with an IC50 value of 14.86 μM. This compound is primarily utilized in the investigation of chronic pain mechanisms and related therapeutic approaches. Its inhibition of COX-2 activity makes it a valuable tool for research into inflammatory processes and pain management strategies. -
COX-2 Inhibitor
COX-2-IN-29 is a selective inhibitor of cyclooxygenase-2 (COX-2), exhibiting an IC50 of 0.005 μM. This compound demonstrates significant anti-inflammatory activity, making it valuable in research focusing on pain modulation and inflammatory disease models. Its oral bioavailability further supports its potential utility in pharmacological studies and therapeutic applications targeting COX-2-related pathways. -
COX-2 Inhibitor
Mefenamic acid-d4 is a deuterated form of Mefenamic acid, which acts as a selective competitive inhibitor of cyclooxygenase-2 (COX-2). This NSAID exhibits significant anti-inflammatory properties, with a notable ability to penetrate the blood-brain barrier. Mefenamic acid-d4 is primarily utilized in pharmacokinetic studies and metabolic research, aiding in the exploration of inflammatory responses and mechanisms of pain relief through its interaction with COX-1 and COX-2 enzymes. -
COX Inhibitor
Ibuprofen Impurity K is a chemical impurity associated with Ibuprofen, a well-known nonsteroidal anti-inflammatory drug (NSAID) that functions as a cyclooxygenase (COX) inhibitor. It selectively inhibits COX-1 with an IC50 of 13 μM and COX-2 with an IC50 of 370 μM, contributing to its anti-inflammatory effects. This compound is relevant for studies focused on the metabolism and safety of Ibuprofen, as well as for research into the pharmacological profiles of COX inhibitors. -
COX Inhibitor
Thiazolinobutazone is a selective cyclooxygenase (COX) inhibitor that exhibits anti-inflammatory properties. This compound is recognized for its reduced toxicity compared to Phenylbutazone, making it a safer alternative in pharmacological research. Thiazolinobutazone is primarily utilized in the investigation of various immunological diseases, providing insights into COX-related pathways and inflammation mechanisms. -
COX Inhibitor
LY150310 free base is a potent COX inhibitor that effectively inhibits thromboxane synthase and cyclooxygenase, as well as thrombin activation. This compound demonstrates a dose-dependent ability to inhibit spontaneous lung metastasis, making it valuable for research applications aimed at understanding metastatic processes and developing anti-cancer therapies. -
COX-2 Inhibitor
COX-2-IN-12 is a selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 of 19.98 μM, demonstrating potent anti-inflammatory properties. This compound is suitable for various biological research applications related to inflammation and pain management. In vivo acute toxicity studies indicate a favorable safety profile for COX-2-IN-12, supporting its potential for therapeutic exploration. -
COX-1 Inhibitor
(+)-Catechin pentaacetate serves as a precursor for the synthesis of (+)-catechin, a natural compound with herbicidal and antimicrobial properties. This compound functions as a selective inhibitor of cyclooxygenase-1 (COX-1), exhibiting an IC50 value of 1.4 μM. Its ability to modulate COX-1 activity makes it valuable for research in inflammation and pain response pathways. -
COX-2 Inhibitor
COX-2-IN-23 is a selective inhibitor of cyclooxygenase-2 (COX-2), exhibiting IC50 values of 0.28 μM for COX-2 and 20.14 μM for COX-1. This compound demonstrates significant anti-inflammatory activity while maintaining a low ulcerogenic profile, making it suitable for research applications focused on inflammation and pain modulation. Its selectivity and efficacy position it as a valuable tool in the study of inflammatory pathways. -
COX Inhibitor
COX-2-IN-50 is a highly soluble COX-2 inhibitor, exhibiting notable analgesic activity. With a water solubility of 20.3 mg/mL, it surpasses its precursor compound, PC407, which has a solubility of 1.6 μg/mL. This compound demonstrates excellent biocompatibility, making it suitable for the formulation of injectable dosage forms. COX-2-IN-50 has shown significant analgesic effects in vivo, indicating its potential in pain management research and therapeutic applications. -
COX Inhibitor
Diclofenac deanol is a potent cyclooxygenase (COX) inhibitor, particularly exhibiting enhanced selectivity for COX-2 over COX-1. This compound possesses anti-inflammatory, analgesic, and antipyretic properties, making it valuable in pain management and inflammation-related research. Its superior water solubility compared to traditional diflunisal salts facilitates its application in various biological assays and medical research, expanding its potential therapeutic uses. -
COX-2 Inhibitor
COX-2-IN-20 is a selective COX-2 inhibitor with a measured IC50 of 17.9 nM. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for research in inflammation and pain management. Its oral bioavailability allows for convenient administration in various studies aimed at understanding COX-2's role in inflammatory diseases. -
COX Inhibitor
Flunixin is a cyclooxygenase (COX) inhibitor that exhibits IC50 values of 0.55 μM for COX-1 and 3.24 μM for COX-2. It is known for its anti-inflammatory properties, making it valuable in studies aimed at understanding inflammatory pathways. Flunixin is commonly utilized in research focused on pain management and related therapeutic applications. -
COX-2 Inhibitor
COX-2-IN-22 is a selective inhibitor of Cyclooxygenase-2 (COX-2) with an IC50 of 8.6 µM. In addition to its primary activity, COX-2-IN-22 also exhibits inhibitory effects on Acetylcholinesterase (AChE), Butyrylcholinesterase (BChE), β-Secretase, Lipoxygenase-5 (LOX-5), and DPPH, with IC50 values of 2.8 µM, 6.3 µM, 15.3 µM, 13.9 µM, and 6.8 µM, respectively. This compound is capable of crossing the blood-brain barrier, making it a valuable tool for research in neuroinflammatory and neurodegenerative disease models. -
COX Inhibitor
2-Hydroxy Ibuprofen is a metabolic derivative of Ibuprofen, functioning primarily as a cyclooxygenase (COX) inhibitor. It demonstrates significant anti-inflammatory activity, targeting COX-1 and COX-2 enzymes with inhibitory concentrations (IC50) of 13 μM and 370 μM, respectively. This compound is valuable for studying the mechanisms of inflammation and pain in various research applications, particularly in pharmacology and toxicology. -
COX-2 Inhibitor
Etoricoxib hydrochloride is a selective COX-2 inhibitor that effectively reduces inflammation and alleviates pain by blocking the conversion of arachidonic acid to prostaglandins. This compound is primarily utilized in research related to osteoarthritis and demonstrates significant anti-inflammatory properties. Additionally, etoricoxib hydrochloride has been shown to promote bone remodeling through enhanced alkaline phosphatase activity. Its formulation, developed using emulsion solvent evaporation technology, ensures good cell compatibility for various biological applications. -
COX-2 Inhibitor
Indomethacin heptyl ester is a selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 of 0.04 μM. This compound demonstrates significant anti-inflammatory activity, making it valuable for studying inflammatory processes and discovering potential therapeutic interventions in diseases characterized by COX-2 overexpression. Its specificity for COX-2 provides insights into the mechanism of action and the development of novel anti-inflammatory agents. -
COX Inhibitor
Indobufen sodium is a reversible inhibitor of cyclooxygenase (COX) activity, primarily targeting platelet aggregation. By suppressing the synthesis of thromboxane A2 (TxA2), it effectively modulates platelet function. Additionally, Indobufen sodium down-regulates the expression of tissue factor (TF) in monocytes, making it a valuable tool for research involving cardiovascular and inflammatory processes. -
COX-2/Aromatase Inhibitor
COX-2/Aromatase-IN-2 is a potent dual inhibitor targeting cyclooxygenase-2 (COX-2) and aromatase. It effectively suppresses inflammation and inhibits cell proliferation in breast cancer models, demonstrating significant anti-cancer and anti-inflammatory activities. Proven efficacy in the MCF-7 breast cancer cell line and carrageenan-induced rat paw edema model makes COX-2/Aromatase-IN-2 a valuable tool for researching inflammation and breast cancer pathways. -
5-LOX/COX-1 Inhibitor
Atractylochromene is a dual inhibitor targeting 5-lipoxygenase (5-LOX) and cyclooxygenase-1 (COX-1), exhibiting IC50 values of 0.6 μM and 3.3 μM, respectively. This compound serves as a valuable tool in research related to inflammatory pathways and can facilitate the study of related conditions influenced by leukotrienes and prostaglandins. Its inhibitory effects position Atractylochromene as a potential candidate for therapeutic exploration in inflammatory diseases. -
XO/COX/LOX Inhibitor
XO/COX/LOX-IN-1 is a potent inhibitor of xanthine oxidase, cyclooxygenases, and lipoxygenases. This compound exhibits significant anti-inflammatory activity, making it valuable for research in inflammation, cancer, and metabolic diseases. Its multifaceted inhibition profile positions XO/COX/LOX-IN-1 as a critical tool for exploring pathways involved in these pathological conditions. -
COX Inhibitor
Axinelline A is a potent cyclooxygenase (COX) inhibitor, demonstrating IC50 values of 2.22 μM for COX-2 and 8.89 μM for COX-1. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for research into inflammatory pathways and potential therapeutic interventions. Axinelline A is suitable for studies focused on the modulation of COX enzymes and the inflammatory response. -
COX-2 Inhibitor
DRF-4848 is a selective inhibitor of cyclooxygenase-2 (COX-2), a key enzyme involved in the inflammatory response. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for studying inflammation-related pathways and diseases. Researchers can utilize DRF-4848 to investigate its effects on pain management and the modulation of inflammatory processes in various biological contexts. -
COX-2 Inhibitor
COX-2-IN-26 is a selective and orally active inhibitor of cyclooxygenase-2 (COX-2) with an IC50 of 0.067 µM, demonstrating its potency. This compound exhibits anti-inflammatory properties, making it a valuable tool for research in inflammation-related studies. Additionally, COX-2-IN-26 is noted for its favorable gastrointestinal safety profile, supporting its potential application in therapeutic development. -
COX-2 Inhibitor
Anti-inflammatory agent 56 is a selective COX-2 inhibitor with an IC50 of 0.54 μM. It demonstrates significant anti-inflammatory and antioxidant properties, effectively reducing oxidative stress-induced cell death. By inhibiting key targets such as Keap1, COX-2, and iNOS, this compound mitigates neuroinflammation and oxidative stress. Furthermore, it exhibits low acute toxicity in murine models, with an LD50 of 1000 mg/kg, making it a valuable tool for research in inflammation and neuroprotection. -
COX-2/LOX Inhibitor
COX-2/5-LOX-IN-4 is a potent dual inhibitor targeting both cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX), with IC50 values of 0.05 μM and 0.003 μM, respectively. By disrupting the arachidonic acid metabolism pathway, this compound effectively decreases the synthesis of prostaglandins and leukotrienes, leading to reduced inflammatory responses. In vivo studies using a rat ear edema model demonstrate its substantial anti-inflammatory activity, with intravenous doses resulting in up to 44% reduction in edema. COX-2/5-LOX-IN-4 is an important tool for investigating the mechanisms underlying inflammatory diseases. -
COX Inhibitor
N-(4-acetamidophenyl)-indomethacin amide is a selective reversible inhibitor of cyclooxygenase-2 (COX-2). It demonstrates potent inhibitory activity against human recombinant and ovine COX-2, with IC50 values of 0.12 μM and 0.625 μM, respectively, while showing significantly lower potency against COX-1 isoforms. This compound is valuable for research applications focused on inflammation, pain management, and the role of COX-2 in various pathological conditions. -
FAAH/COX Inhibitor
Carpro-AM1 is a dual-acting inhibitor targeting fatty acid amide hydrolase (FAAH) and selectively inhibiting cyclooxygenase (COX) enzymes. This compound exhibits an IC50 value of 94 nM for FAAH, demonstrating significant biological activity in regulating endocannabinoid signaling. Carpro-AM1 is suited for research applications focusing on pain management, inflammation, and the modulation of the endocannabinoid system. -
COX-2 Inhibitor
COX-2-IN-33 is a selective COX-2 inhibitor with an IC50 of 45.5 nM, designed for research into inflammatory pathways. This compound demonstrates significant inhibition of pro-inflammatory cytokine production in vivo, indicating its potential as an anti-inflammatory agent while maintaining gastric safety. It is particularly useful for studies focused on chronic inflammation and pain management. -
COX Inhibitor
4'-Aarboxylic acid imrecoxib is a metabolite of Imrecoxib, targeting the cyclooxygenase-2 (COX-2) enzyme. It exhibits anti-inflammatory properties through the inhibition of COX-2, making it valuable for research in pain management and inflammatory disorders. This compound can be utilized in studies focused on the modulation of prostaglandin synthesis. -
COX Inhibitor
Eltenac is a non-steroidal anti-inflammatory drug (NSAID) that acts as a cyclooxygenase (COX) inhibitor, demonstrating IC50 values of 0.03 μM for both COX-1 and COX-2 in isolated human whole blood. Its potent inhibitory activity against COX enzymes makes it valuable in studying inflammatory pathways and evaluating potential therapeutic applications related to pain and inflammation management. Researchers can utilize Eltenac in various experimental settings to explore the role of COX in disease processes. -
COX Inhibitor
Butanixin is a cyclooxygenase (COX) inhibitor that demonstrates significant anti-inflammatory and analgesic properties through the reduction of prostaglandin synthesis. This compound is primarily utilized in the research of musculoskeletal disorders, providing valuable insights into therapeutic mechanisms targeting inflammation and pain management. Its effectiveness in modulating COX activity makes it a relevant tool for investigating inflammatory pathways. -
COX-2/15-LOX Inhibitor
COX-2/15-LOX-IN-7 is a selective dual inhibitor targeting cyclooxygenase-2 (COX-2) and 15-lipoxygenase (15-LOX) with IC50 values of 0.022 and 1.19 μM, respectively. It also demonstrates inhibition of COX-1 with an IC50 of 28.081 μM. This compound exhibits low cytotoxicity in human colorectal cancer cell lines (HT-29 and HCT116) with IC50 values exceeding 100 μM, and shows a non-ulcerogenic profile. COX-2/15-LOX-IN-7 is valuable for cancer research applications, facilitating the study of inflammatory pathways and therapeutic interventions. -
COX-1 Inhibitor
Ethoxycoronarin D is a labdane diterpene that functions as a selective inhibitor of cyclooxygenase-1 (COX-1), exhibiting an IC50 value of 3.8 µM. This compound demonstrates significant anti-inflammatory activity and has potential applications in research related to pain management and various inflammatory conditions. Its selective inhibition of COX-1 may provide insights into the mechanisms underlying inflammation and pain pathways. -
COX/5-LOX Inhibitor
CI-986 is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX), effectively preventing coronary vasoconstriction and the excessive production of leukotrienes, including LTB4 and LTC4. This compound exhibits notable anti-inflammatory and analgesic properties, making it a valuable tool for research into inflammation and cardiovascular diseases, including conditions like arthritis. CI-986's unique mechanism positions it as an important reagent in studies focused on the modulation of inflammatory pathways and vascular health. -
COX
PPHP is a substrate designed for the quantitative assessment of cyclooxygenase (COX) enzymes. It specifically permits the measurement of peroxidase activity in both COX-1 and COX-2. This compound is valuable for research applications focused on inflammation, pain pathways, and the biochemical characterization of COX-related functions.
